We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults assigned 15 mg VK2735 lost 14.7% of their body ...
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results